FIELD: biochemistry.
SUBSTANCE: invention relates to a genetically modified mouse to form T-cell mediated immune responses, as well as a method for production thereof. Also disclosed are a T-cell, a hybridoma and an embryonic stem cell derived from said mouse, as well as a method of producing a TCR protein which is antigen-specific and contains a human variable TCR domain, method of producing a human variable TCR domain of a TCR protein which is specific to an antigen, as well as a method of producing a nucleic acid sequence encoding a human variable TCR domain of the TCR protein. Invention also relates to a composition for evaluating a humanised T-cell immune response among murine cells, wherein the composition comprises a first and a second cell of said mouse.
EFFECT: invention can be effectively used for developing therapeutic agents for humans.
41 cl, 15 dwg, 9 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENETICALLY MODIFIED T CELL RECEPTOR MICE | 2012 |
|
RU2661106C2 |
| NON-HUMAN ANIMALS EXPRESSING EXOGENOUS TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE | 2017 |
|
RU2753585C2 |
| GENETICALLY MODIFIED MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES | 2012 |
|
RU2660564C2 |
| GENETICALLY MODIFIED ANIMALS OTHER THAN HUMANS FOR PRODUCING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS FOR PRODUCTION AND VERSIONS OF USE THEREOF | 2019 |
|
RU2819525C2 |
| GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE | 2012 |
|
RU2653433C2 |
| GENETICALLY MODIFIED MICE EXPRESSING CHIMERIC MOLECULES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX | 2012 |
|
RU2797549C2 |
| METHOD FOR OBTAINING T-CELL RECEPTOR EXPRESSING CELLS | 2013 |
|
RU2665548C2 |
| NON-HUMAN ANIMALS EXPRESSING HUMANISED COMPLEX CD3 | 2015 |
|
RU2726446C2 |
| GENETICALLY MODIFIED MHISTOCOMPATIBILITY COMPLEX MICE | 2012 |
|
RU2783984C2 |
| GENETICALLY MODIFIED MICE FOR T-CELL RECEPTOR | 2012 |
|
RU2797272C1 |
